Photo shows an announcement released by China Meheco, Dec. 12, 2022. (Screenshot Photo)
China Meheco said on Wednesday it signed an agreement with Pfizer Inc to import and distribute its oral COVID-19 treatment Paxlovid in the Chinese mainland.
The agreement is valid between Dec. 14 and Nov. 30, 2023, China Meheco said in its announcement.
